Y-mAbs Therapeutics (YMAB) is down some 65% since my coverage in May after it failed to win approval for neuroblastoma therapy I-omburtamab. The molecule Omblastys (omburtamab) was granted a priority ...
Y-mAbs Therapeutics has experienced a significant recovery in value but lacks upcoming catalysts for near-term growth. Their approved therapy, naxitamab, has shown promising results in treating ...
In a recent study published in the Annals of Internal Medicine, researchers assess the efficacy of monoclonal antibodies (mAbs) in treating coronavirus disease 2019 (COVID-19) caused by different ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results